Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells

被引:28
|
作者
Lebedeva, I. V.
Su, Z-Z
Emdad, L.
Kolomeyer, A.
Sarkar, D.
Kitada, S.
Waxman, S.
Reed, J. C.
Fisher, P. B. [1 ]
机构
[1] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA
[2] Columbia Univ, Coll Phys & Surg, Med Ctr, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY USA
[3] Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA
[4] Burnham Inst, La Jolla, CA USA
[5] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA
关键词
mda-7/IL-24; K-ras single-chain antibody; K-ras AS; bipartite adenovirus; colorectal carcinoma; Bcl-family of proteins;
D O I
10.1038/sj.onc.1209813
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in similar to 40-50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.
引用
收藏
页码:733 / 744
页数:12
相关论文
共 50 条
  • [31] Detection of mutant K-RAS sequences in the urine of cancer patients
    Serdyuk, OI
    Botezatu, IV
    Shelepov, VR
    Potapova, GI
    Alekhina, RP
    Molyaka, YK
    Anan'ev, VS
    Knysh, VI
    Melkonyan, OS
    Umanskii, SR
    Lichtenshtein, AV
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2001, 131 (03) : 283 - 284
  • [32] Detection of Mutant K-RAS Sequences in the Urine of Cancer Patients
    O. I. Serdyuk
    I. V. Botezatu
    V. P. Shelepov
    G. I. Potapova
    R. P. Alekhina
    Yu. K. Molyaka
    V. S. Anan'ev
    V. I. Knysh
    O. S. Melkonyan
    S. R. Umanskii
    A. V. Lichtenshtein
    Bulletin of Experimental Biology and Medicine, 2001, 131 : 283 - 284
  • [33] Molecular consequences of silencing mutant K-ras in pancreatic cancer cells:: Justification for K-ras-directed therapy
    Fleming, JB
    Shen, GL
    Holloway, SE
    Davis, M
    Brekken, RA
    MOLECULAR CANCER RESEARCH, 2005, 3 (07) : 413 - 423
  • [34] Targeting β-Catenin in Hepatocellular Cancers Induced by Coexpression of Mutant β-Catenin and K-Ras in Mice
    Tao, Junyan
    Zhang, Rong
    Singh, Sucha
    Poddar, Minakshi
    Xu, Emily
    Oertel, Michael
    Chen, Xin
    Ganesh, Shanthi
    Abrams, Marc
    Monga, Satdarshan P.
    HEPATOLOGY, 2017, 65 (05) : 1581 - 1599
  • [35] Targeting IL-1β as a Preventive Modality for K-ras Mutant Lung Cancer
    Yuan, B.
    Clowers, M. J.
    Velasco, W. V.
    Ramos-Castaneda, M.
    Peng, S.
    Moghaddam, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [36] Gene therapy of pancreatic cancer targeting the K-Ras oncogene
    V Lisiansky
    I Naumov
    S Shapira
    D Kazanov
    A Starr
    N Arber
    S Kraus
    Cancer Gene Therapy, 2012, 19 : 862 - 869
  • [37] MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo
    S Vidic
    B Markelc
    G Sersa
    A Coer
    U Kamensek
    G Tevz
    S Kranjc
    M Cemazar
    Cancer Gene Therapy, 2010, 17 : 409 - 419
  • [38] MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo
    Vidic, S.
    Markelc, B.
    Sersa, G.
    Coer, A.
    Kamensek, U.
    Tevz, G.
    Kranjc, S.
    Cemazar, M.
    CANCER GENE THERAPY, 2010, 17 (06) : 409 - 419
  • [39] Analysis of K-ras mutations in the stool of patients with colorectal cancer
    Pagani, R
    Porcelli, B
    Forsi, B
    Civitelli, S
    Mancini, A
    Civitelli, B
    Tanzini, G
    Marinello, E
    MINERVA BIOTECNOLOGICA, 1996, 8 (03) : 142 - 144
  • [40] K-ras codon 12 mutation determines the polypoid growth of colorectal cancer
    Chiang, JM
    Chou, YHW
    Chou, TB
    CANCER RESEARCH, 1998, 58 (15) : 3289 - 3293